“Lupus Nephritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.
The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Lupus Nephritis Pipeline Report:
Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment
Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
In February 2024, ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its Phase Ib/II clinical trial of IMPT-514, aimed at treating refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a CD19/CD20-targeting bispecific chimeric antigen receptor (CAR) T-cell therapy designed to deplete autoreactive immune cells. This open-label dose escalation trial will enroll participants with active, refractory SLE who have previously undergone at least two standard-of-care therapies.
In September 2023, Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing treatments for serious autoimmune diseases, announced that KYV-101 was generally well tolerated with no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the standard 28-day post-infusion observation period for the first U.S. patient enrolled in its Phase 1 clinical trial for relapsed or refractory lupus nephritis (LN). The KYV-101 infusion took place earlier in July at the University of Colorado Anschutz Medical Campus.
In July 2023, Kyverna Therapeutics (“Kyverna”), a cell therapy company with the goal of creating a new class of treatments for severe autoimmune diseases, announced today that the Paul-Ehrlich-Institut (PEI) in Germany has approved its first Clinical Trial Application (CTA) for KYV101, a cutting-edge therapy for the treatment of lupus nephritis (LN). In order to treat autoimmune disorders caused by B cells, such as LN, KYV-101 is a unique, totally human anti-CD19 CAR T-cell therapy. It provides a ground-breaking strategy for battling autoimmune diseases by utilising the body’s immune system
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease where the body’s immune system mistakenly attacks its own tissues. In lupus nephritis, the immune system targets the kidneys, leading to inflammation and potentially causing kidney damage.
Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight
Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:
Secukinumab: Novartis
Obinutuzumab: Roche
GAZYVA: Roche
Saphnelo (Anifrolumab): AstraZeneca
Iscalimab: Novartis
IBL-101: Inflection Biosciences
RG 6107: Roche
Itolizumab: Equillium
Zanubrutinib: BeiGene
Guselkumab: Janssen Research & Development
Daxdilimab: Horizon Therapeutics
Cosentyx: Novartis
Ravulizumab: Alexion Pharmaceuticals
Anifrolumab: AstraZeneca
Lupus Nephritis Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Lupus Nephritis Molecule Type
Lupus Nephritis Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Lupus Nephritis Pipeline Therapeutics Assessment
Lupus Nephritis Assessment by Product Type
Lupus Nephritis By Stage and Product Type
Lupus Nephritis Assessment by Route of Administration
Lupus Nephritis By Stage and Route of Administration
Lupus Nephritis Assessment by Molecule Type
Lupus Nephritis by Stage and Molecule Type
DelveInsight’s Lupus Nephritis Report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies
Some of the key companies in the Lupus Nephritis Therapeutics Market include:
Key companies developing therapies for Lupus Nephritis are – Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
Lupus Nephritis Pipeline Analysis:
The Lupus Nephritis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies
Lupus Nephritis Pipeline Market Drivers
Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.
Lupus Nephritis Pipeline Market Barriers
However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.
Scope of Lupus Nephritis Pipeline Drug Insight
Coverage: Global
Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials
Table of Contents
1. Lupus Nephritis Report Introduction
2. Lupus Nephritis Executive Summary
3. Lupus Nephritis Overview
4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment
5. Lupus Nephritis Pipeline Therapeutics
6. Lupus Nephritis Late Stage Products (Phase II/III)
7. Lupus Nephritis Mid Stage Products (Phase II)
8. Lupus Nephritis Early Stage Products (Phase I)
9. Lupus Nephritis Preclinical Stage Products
10. Lupus Nephritis Therapeutics Assessment
11. Lupus Nephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Lupus Nephritis Key Companies
14. Lupus Nephritis Key Products
15. Lupus Nephritis Unmet Needs
16 . Lupus Nephritis Market Drivers and Barriers
17. Lupus Nephritis Future Perspectives and Conclusion
18. Lupus Nephritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
